TSLP, Une Nouvelle Cible Thérapeutique Potentielle Pour Le Traitement De L’asthme Allergique

F. Madouri,V. Quesniaux,B. Ryffel,D. Togbe
DOI: https://doi.org/10.1016/j.reval.2013.01.046
IF: 0.254
2013-01-01
Revue Française d'Allergologie
Abstract:Allergic asthma is in clear expansion in industrialized countries, increasing both in prevalence and severity. The mechanisms of sensitization and the triggering of asthma are complex. This disease is associated with a Th2-cell immune response in which IL-4, IL-13, IgE, IL-5 and thymic stromal lymphopoetin (TSLP) are involved. A Th17 component, which secretes IL-17 and IL-22, has likewise been linked to allergic asthma. TSLP is a type 1 cytokine associated with the cellular and molecular mechanisms of allergic asthma. In this review, we will summarize the functions of TSLP on various cell types and its role in allergies, giving particular attention to cells producing IL-17 and IL-22 in allergic asthma. (C) 2013 Elsevier Masson SAS. All rights reserved.
What problem does this paper attempt to address?